Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer.
Saved in:
| Title: | Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer. |
|---|---|
| Authors: | McLaughlin S; Massachusetts General Hospital, Boston, MA, USA., Nakajima E; Massachusetts General Hospital, Boston, MA, USA., Bar Y; Massachusetts General Hospital, Boston, MA, USA., Hutchinson JA; Massachusetts General Hospital, Boston, MA, USA., Shin J; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Moy B; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Isakoff SJ; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Bardia A; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Kuter I; Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Spring LM; Attending Physician, Massachusetts General Hospital Cancer Center, Harvard Medical School, Bartlett Hall, 40R Blossom St., Boston, MA 02114, USA. |
| Source: | Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2023 Jan 10; Vol. 15, pp. 17588359221146133. Date of Electronic Publication: 2023 Jan 10 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Sage Country of Publication: England NLM ID: 101510808 Publication Model: eCollection Cited Medium: Print ISSN: 1758-8340 (Print) Linking ISSN: 17588340 NLM ISO Abbreviation: Ther Adv Med Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1758-8340 |
|---|---|
| DOI: | 10.1177/17588359221146133 |
